A subset of papillary renal cell carcinomas (RCC) is characterized by the expression of a TFE3 fusion protein, where the fusion partner can be any of the several proteins identified so far such as PSF (PTB associated splicing factor), NonO, PRCC, CLTC and ASPL. These proteins result from chromosomal translocations involving the TFE3 gene located on the X chromosome. Our present study documents the central role of PSF-TFE3 in oncogenic transformation. We show that the inhibition of PSF-TFE3 expression through siRNA or shRNA leads to impaired growth, proliferation, invasion potential and long-term survival of UOK-145 papillary renal carcinomaderived cells, which endogenously express PSF-TFE3. The oncogenic potential of PSF-TFE3 became evident by stable expression of PSF-TFE3 in NIH-3T3 mouse fibroblast cells, which leads to the acquisition of anchorage-independent growth as revealed by soft agar assay. In addition, the expression of PSF-TFE3 in normal renal proximal tubular epithelial cells from where such tumors originate leads to dedifferentiation and loss of some key functional proteins, which may reflect an initial step in the multistep process of tumor development. This suggests that the expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary RCC. Oncogene (2007 Oncogene ( ) 26, 277-283. doi:10.1038 ; published online 10 July 2006
Keywords: PSF-TFE3; siRNA; growth inhibition; apoptosis; transformation; dedifferentiation Renal cell carcinoma (RCC) is a highly heterogeneous disease that consists of various subtypes based on their genetics and morphological features (Kovacs et al., 1997; Storkel et al., 1997) . A broad classification of RCC includes the histological subtypes: clear cell, papillary, chromophobe, and collecting duct. Out of these, the clear cell carcinomas are the most prevalent and constitute up to 80-85% of the presented cases. Clear cell tumors exhibit a frequent loss of 3p regions, 3p21, 3p12-14 and 3p25. Loss of heterozygosity (LOH) and somatic mutation of the VHL (Von Hippel-Lindau) tumor suppressor gene located on chromosome 3p25 is a common finding in sporadic clear cell carcinomas (Morrissey et al., 2001; Wiesener et al., 2001; Bodmer et al., 2002; Yang et al., 2003; Guo et al., 2004) . The second most common type is papillary RCCs with tumor cells arranged in papillary configuration and are characterized by trisomies (chromosomes 3q, 7, 12, 16, 17 and 20) and loss of the Y chromosome in male patients (Lindor et al., 2001; Sanders et al., 2002) . The other most common cause for papillary RCCs that has been identified in the last few years is the translocation or inversion between the TFE3 gene located on chromosome X (p11.2) and several other genes (Argani et al., , 2003 Ladanyi et al., 2001; Skalsky et al., 2001; Weterman et al., 2001b; Bennicelli and Barr, 2002; Bodmer et al., 2002; Mathur et al., 2003) . These translocations lead to the expression of TFE3 chimeras of PSF (1p34), PRCC (1q21), RCC17 (17q25.3) or CLTC (17q23) and an inversion on the X chromosome leads to . In every case the DNA-binding domain of TFE3 is retained. These tumors involving translocation of the TFE3 gene seem to primarily affect children and young adults and form a separate subclass of papillary RCCs.
Our previous studies with a PSF-TFE3 expressing cell line (UOK-145) derived from a papillary RCC indicated that unlike PSF, PSF-TFE3 is an extranuclear protein and acts through sequestration of TFE3 and p53 and possibly other factors in the extranuclear compartment. This also results in the loss of transcriptional activity of these two factors. Downregulation of PSF-TFE3 by siRNA leads to relocalization of p53 and TFE3 to the nucleus (Mathur et al., 2003) . We now show that highlevel expression of PSF-TFE3 is essential for growth, invasion, proliferation and survival of these cells. We also document the oncogenic potential of PSF-TFE3 by its stable expression in NIH-3T3 cells. The expression of PSF-TFE3 in renal proximal tubule epithelial cells from where these tumors originate leads to dedifferentiation and loss of some key functional proteins, suggesting that PSF-TFE3 is required for the initiation as well as maintenance of transformed phenotype during tumor development and progression.
To further evaluate the specificity of siRNA designed to target PSF-TFE3, another double-stranded siRNA with the same sequence that differed in only three bases (mismatched siRNA, MsiRNA) was also tested in UOK-145 cells. A 21 bp siRNA complementary to the PSF-TFE3 mRNA fusion junction (5 0 -AA GUG ACA UGC UGC CUG UGU C-3 0 ) and a mismatched siRNA (MsiRNA) that has three base changes in the middle of siRNA sequence (5 0 -AA GUG ACA UGA GUC CUG UGU C-3 0 ) were synthesized by Dharmacon Research Inc., Lafayette, CO, USA. As shown in Figure 1a , there is a B70-80% reduction in the expression levels of PSF-TFE3 only when cells are transfected with a perfectly matched siRNA. However, the siRNA that differed The invaded cells were also manually counted under the microscope and the percent invasion was calculated for each cell type.
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M Mathur and HH Samuels from the original sequence by only three bases failed to have any effect on the levels of PSF-TFE3. The expression levels of PSF-TFE3 modulated by siRNA are also important for relocalization of p53 and TFE3. These cells were also immunostained with anti-p53 or anti-TFE3 antibody followed by incubation with fluorescein-conjugated secondary antibodies. As shown in Figure 1b , the mismatched siRNA has no effect on the relocalization of p53 or TFE3 to the nucleus. However, the cells transfected with a perfectly matched siRNA show nuclear localized p53 and TFE3. For stable knockdown of PSF-TFE3 in UOK-145 cells, a double-stranded DNA sequence encoding a short hairpin RNA (shRNA) that can be processed in the cells to generate siRNA complementary to the fusion junction in PSF-TFE3 mRNA was cloned into a retroviral expression vector (pSIREN-RetroQ vector from Clontech). The virus produced from this construct and the parent pSIREN-RetroQ vector that served as a control was used to infect UOK-145 cells. Cells were selected with 2 mg/ml puromycin and equal amounts of total protein lysate prepared from these cells were fractionated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with anti-TFE3 antibody. As shown in Figure 1c there is a significant decrease in the levels of PSF-TFE3 in the cells that express shRNA.
After establishing an shRNA system to downregulate the expression of PSF-TFE3, we investigated the various morphological and biological changes occurring in these cells. Initially, we examined if the stable knockdown of PSF-TFE3 is sufficient to have a significant effect on the cell growth and proliferation. Cells were plated in 12-well plates and allowed to grow for 5-6 days, and then fixed and stained with crystal violet to visualize the colonies. Cells expressing shRNA complementary to PSF-TFE3 exhibited slower growth and were unable to form large colonies compared to the cells that did not express this shRNA (Figure 1d ). Cells from each set were also trypsinized and total number of viable cells evaluated by Trypan blue exclusion counting are presented in Figure 1e as an average of three independent experiments.
The other property of the cancer cells that is responsible for metastasis is their invasive potential that allows them to invade through the barrier of the basement membrane and helps them to escape from the primary tumor site. We wanted to test if a low level of PSF-TFE3 compromises the invasive potential of UOK-145 cells. The cells stably expressing shRNA against PSF-TFE3 and the control cells were subjected to Matrigel invasion assay as described in Albini et al. (1987) . After 48 h the cells that migrated through the Matrigel and attached to the underside of the membrane were examined in different fields. UOK-145 cells transformed with the control virus invaded the Matrigel. However, the cells expressing the shRNA failed to show any invasion (Figure 1f ). In the same experiment T47D breast cancer cells served as a positive control. The number of invaded cells were also manually counted under the microscope and percent invasion was calculated for each cell type (Figure 1g ).
To further evaluate if the high levels of PSF-TFE3 in UOK-145 cells are required for their long-term survival, cells were also examined for apoptosis when PSF-TFE3 expression levels were reduced. This was initially tested by transiently transfecting the UOK-145 cells with chemically synthesized double-stranded siRNA. Transfected cells were subjected to immunostaining with anti-TFE3 or anti-p53 antibodies followed by TdT-mediated dUTP nick end labeling (TUNEL) assay using Texasred-conjugated dUTP. As shown in Figure 2a , the mock-transfected cells (control) show a cytoplasmic distribution of p53 and TFE3. However, the cells transfected with siRNA that have nuclear localized TFE3 and p53 are also positive for apoptosis. The UOK-145 cells stably expressing shRNA were examined by TUNEL assay using fluorescein-conjugated ApoAlert DNA fragmentation assay kit and they tested positive for apoptosis as well (Figure 2b) .
Thus, the reduction of PSF-TFE3 in UOK-145 cells curtails the high proliferation rate of these cells, their invasion potential and also leads to apoptosis. These observations would suggest a major role for PSF-TFE3 in maintaining the transformed phenotype of UOK-145 Oncogenic effects of PSF-TFE3 M Mathur and HH Samuels cells. The remaining residual levels of PSF-TFE3 expressed in these cells do not seem sufficient to sequester TFE3 or p53 in the cytoplasm. Their relocalization in the nucleus possibly leads to these phenotypes, although there might be other factors involved that possibly contribute to this process.
To examine the specificity of siRNA synthesized for PSF-TFE3, we also tested a number of cell lines that do not express PSF-TFE3 but they failed to show any sign of apoptosis (data not presented), suggesting that the siRNA complementary to PSF-TFE3 is very specific and thus can be used to target this oncoprotein for growth inhibition and proliferation of such tumors.
Our results indicate that the low levels of PSF-TFE3 in UOK-145 cells leads to decreased growth and proliferation and eventual cell death. This suggests that PSF-TFE3 is essential to maintain the oncogenic phenotype of UOK-145 cells. However, no information is available if PSF-TFE3 expression in other cell types would lead to transformation. For such studies mouse NIH-3T3 cells have been used extensively to study the transformation of several cellular and viral oncogenes (Weterman et al., 2001a) .
For expression of PSF-TFE3, we cloned full-length PSF-TFE3 into a retroviral vector (pLPC) and transformed the NIH-3T3 cells with the virus supernatant produced from PSF-TFE3-pLPC construct. The cells infected with control virus produced from the empty vector served as a control. Equal amount of lysate protein prepared from the stable transformants were analysed by Western blotting with anti-TFE3 antibody to detect the expression levels of PSF-TFE3. Total lysates from UOK-145 cells served as a positive control. As shown in Figure 3a , high levels of PSF-TFE3 expression was observed in cells transformed with virus obtained from the PSF-TFE3-pLPC. The control NIH-3T3 cells do not show any corresponding immunoreactive band.
We did not observe any distinct difference in the growth pattern when cells were grown in the tissue culture flasks, except for the appearance of some foci in the PSF-TFE3 expressing cell population. However, the transformed cells exhibited a distinct growth advantage when they were plated on Matrigel basement membrane that mimics an in vivo growth environment in tissue culture Radisky et al., 2001) . The cells expressing PSF-TFE3 showed robust growth and formed large, compact colonies as compared to much smaller and open colonies in the control set (Figure 3b ). To obtain a homogeneous population of NIH-3T3 cells expressing high levels of PSF-TFE3, the individual colonies growing on Matrigel were isolated and propagated further in tissue culture dishes. All the clones showed more or less similar characteristics.
NIH-3T3 cells expressing PSF-TFE3 were also tested for their growth patterns and branching morphogenesis, when grown embedded within the Matrigel. Cells expressing PSF-TFE3 exhibit network growth-like structures, that may reflect their invasive potential (Gao et al., 2005) , as compared to the control cells that formed small colonies with no sign of invasion (Figure 3c ).
These cells were also subjected to soft agar assay to examine their anchorage-independent growth potential. Primary fibroblast cells do not grow when suspended in a viscous fluid or gel and must attach to a solid surface before they can divide. However, upon transformation they exhibit anchorage-independent growth, which is usually considered a stringent assay for transformation. Stably transformed NIH-3T3 cells were seeded in 0.4% agar layered on top of the base layer of 0.8% agar. T47D breast cancer cells plated at the same density served as a positive control. Cells were plated in triplicate for each set. As shown in Figure 4a , in To study the growth pattern on Matrigel, it was diluted 1:1 with growth media and 500 ml of this mixture was applied on the two chambered glass slides in the cold and was left to solidify at 371C. Equal number of cells from control and PSF-TFE3 expressing cells (2.5 Â 10 4 ) suspended in 2 ml of complete growth media were plated on the Matrigel, and were allowed to grow for 2-3 days in the incubator. NIH-3T3 cells that express PSF-TFE3 show robust growth and form large colonies, as compared to the control cells that do not express this protein. (c) To study the growth pattern of cells embedded within the Matrigel, the cell suspension was mixed with Matrigel in a 1:1 ratio and plated on the layer of Matrigel in a two chambered slide. Complete media was added on the top after the Matrigel was solidified. The cells expressing PSF-TFE3 show a network-like growth structure indicative of its invasive growth potential. In contrast, the control cells grow as small colonies.
M Mathur and HH Samuels 3 weeks NIH-3T3 cells expressing PSF-TFE3 grow into large colonies as compared to the cells that do not express this protein. T47D cells also exhibit a similar size and number of colonies. The transformation efficiency for each cell type is presented in Figure 4b as percentage of transformation. Our previous studies in UOK-145 cells (Mathur et al., 2003) showed that PSF-TFE3 localizes to the extranuclear compartment and acts to sequester TFE3 and p53 outside the cell nucleus. We were interested to determine if PSF-TFE3 would act in a similar manner to sequester TFE3 and p53 if expressed in NIH-3T3 cells. As shown in Figure 4c GFP-TFE3 and GFP-p53 are nuclear localized in all control NIH-3T3 cells. However, GFP-TFE3 and GFP-p53 were found sequestered in the extranuclear compartment in NIH-3T3 cells expressing PSF-TFE3.
Our studies in NIH-3T3 cells support the notion that PSF-TFE3 is an oncoprotein and its expression in NIH-3T3 cells leads to transformation. However, the translocations involving the TFE3 and PSF genes resulting in the expression of PSF-TFE3 is primarily reported in RCC. Therefore, the effect of PSF-TFE3 expression in primary kidney cells may provide additional insights into the mechanism(s) of papillary RCC development. To study the role of PSF-TFE3 in kidney epithelial cells, we utilized renal proximal tubular epithelial (RPTE) cells that can be grown in culture in a defined media and still retain their capability to differentiate when plated on Matrigel basement membrane.
In the present study RPTE cells were engineered to express full-length PSF-TFE3 using a retroviral vector as described for NIH-3T3 cells and after selection with puromycin, the positive clones were pooled to avoid clonal variation. Total protein lysate prepared from these cells was subjected to Western blotting with anti-TFE3 antibody to detect the expression levels of PSF-TFE3. As shown in Figure 5a , only the RPTE cells transformed with PSF-TFE3-pLPC express PSF-TFE3 (lanes 2 and 3). No corresponding immunoreactive protein band was detected in the control cells (lane 4). Total cell lysates prepared from UOK-145 cells served as a positive control (lane 1).
A distinguishing feature of renal tubule epithelial cells, which is critical for the maintenance of a highly differentiated epithelial phenotype, is the formation of a primary sensory cilium on the apical pole (Orosz et al., 2004) . The primary cilia extend from the apical surface into the tubular lumen in mammalian nephrons and serve as a sensory organelle, mainly as a mechanosensor. Early passage cultures of RPTE cells growing in tissue culture dishes show no such characteristic features of primary tubule epithelial cells. However, when plated and grown on Matrigel for 24-48 h, they exhibit a distinct feature of terminal differentiation characterized by cilium at their apical poles as shown in Figure 5b . The RPTE cells stably expressing PSF-TFE3 show no such structures; instead they grow in groups of large round cells. We infer that PSF-TFE3 expression in these cells leads to dedifferentiation and loss of characteristic features of renal epithelial cells.
The loss of differentiation may also lead to loss of some key proteins in proximal tubule epithelial cells that are actively involved in functions like Na-Pi Figure 4 Expression of PSF-TFE3 in NIH-3T3 cells leads to transformation. (a) Control and NIH-3T3 cells expressing PSF-TFE3 (10 5 cells in 6 ml of 0.4% agar) were plated on a layer of 4 ml of 0.8% agar (noble agar from Difco) in complete media in 60 mm tissue culture dishes and were incubated in a humidified chamber at 371C with 5% CO 2 . After 1 week, 1 ml of complete media was added to these plates. After 2-3 weeks NIH-3T3 cells expressing PSF-TFE3 form large colonies as compared to the control cells that fail to show any anchorage-independent growth. Breast cancer cells (T47D) served as a positive control. (b) Transformation efficiency of each cell line was calculated by manual counting of colonies and single cells in different microscopic fields and plotted graphically using the formula: Transformation efficiency (%) ¼ number of colonies Â 100/number of colonies þ number of single cells. (c) Cells plated on glass coverslips were transfected with 500 ng of plasmid DNA expressing GFP-TFE3 or GFP-p53 per well using lipofectamine reagent. After 48 h they were fixed with 3.7% formaldehyde and incubated with Hoechst stain for nuclear staining. The control NIH-3T3 cells that do not express PSF-TFE3 show nuclear localized GFP-TFE3 and GFP-p53 (left panel), however the cells expressing PSF-TFE3 show extranuclear distribution of reabsorption, mainly carried out by transporter proteins like Na-Pi cotransporter or NPT2 (Murer et al., 2000) . Na-Pi cotransporter protein II has eight transmembrane domains, glycosylation sites in the extracellular loop and numerous potential phosphorylation sites for protein kinase C and casein II kinases. It has an apparent molecular mass of 80-90 kDa and also forms multimeric high molecular weight structures of 170-200 kDa. To study the expression of NPT2 protein in normal RPTE cells and the cells expressing PSF-TFE3, total cell lysates were fractionated in SDS gels and immunoblotted with anti-NPT2 antibody. As shown in Figure 5c , a 170 kDa band corresponding to NPT2 was identified in the normal RPTE cells, but not in RPTE cells expressing PSF-TFE3 or UOK-145 cells. This 170 kDa band represents a multimeric structural complex of NPT2 found in these cells. We did not detect any 80-90 kDa NPT2 under our extraction conditions. Immunocytochemistry studies were also performed to study the expression and distribution pattern of NPT2. Figure 5d shows the membrane and cytoplasmic distribution of NPT2 in normal RPTE cells but negligible expression in cells expressing PSF-TFE3. 
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The renin-angiotensin system (RAS) plays a major role in the development and maintenance of kidney structure and function. The G-protein-coupled heptathelical angiotensin receptors (AT1 and AT2) are responsible for mediating the biological activity of angiotensin II produced by RAS. Of the two receptors, AT1 is expressed throughout the kidney and plays a major role in renal sodium handling by modulating epithelial sodium transport (Le et al., 2004) . In a recent study, the cellular localization and membrane trafficking of AT1 receptor was studied in mouse proximal tubule cells . It was shown that this apical membrane protein recycles through an intracellular compartment termed 'condensed apical recycling endosomes' (CARE). In differentiated cells the vesicles containing AT1 receptors relocate to the subapical region and give rise to a distinct lobular ring-like structure.
Western blotting studies (Figure 5e ) show no overall change in the expression level of AT1 in cells expressing PSF-TFE3. However, the distribution pattern changes dramatically from a condensed ring structure to a more dispersed distribution throughout the cytoplasm when PSF-TFE3 is expressed in these cells (Figure 5f ). We envisage that expression of PSF-TFE3 in these cells may either sequester or somehow interfere with the targeting of AT1 to CARE. As the distribution of AT1 receptor is also dependent on the microtubule cytoskeleton, the disassembly of microtubules reported in cancer cells may also be responsible for its dispersion.
In summary, we show that PSF-TFE3 is essential for growth and survival of UOK-145 cells. The expression of PSF-TFE3 leads to a transformed phenotype in NIH-3T3 cells and its expression in renal epithelial cells, leads to initiation of transformation, as evident by dedifferentiation, loss of their typical phenotypic features and the loss of some key functional proteins. Thus, we infer that PSF-TFE3 plays a dual role of initiation and maintenance of the transformed phenotype in cancer cells. Our study suggests that PSF-TFE3, and possibly other TFE3 fusion proteins found in some papillary RCCs, play an important role in the oncogenic phenotype and thus may serve as an ideal target for the treatment of such tumors.
